Vnitr Lek 2007, 53(6):653-661

Essential thrombocytemia and other myeloproliferations with thrombocytemia in the data of the register of patients treated with Thromboreductin® till the end of 2006

M. Penka1,*, J. Schwarz2, T. Pavlík3, R. Pytlík4, M. Doubek5, P. Dulíček6, D. Pospíšilová7, J. Kissová1, A. Hluší8, M. Schützová9, O. Černá10, Y. Brychtová3, T. Szotkowski8, Z. Volková2, J. Seghetová11, V. Vozobulová9, I. Hadačová11, I. Hochová11, J. Voglová6, T. Lhoťanová12, B. Bubeník13, O. Zapletal1, M. Vránová14, M. Mičaníková14, L. Dušek3
1 Oddělení klinické hematologie FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Miroslav Penka, CSc.
2 Ústav hematologie a krevní transfuze Praha, ředitel prof. MUDr. Pavel Klener, DrSc.
3 Institut biostatistiky a analýz MU Brno, přednosta doc. RNDr. Ladislav Dušek, CSc.
4 I. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Pavel Klener, DrSc.
5 Interní hematoonkologická klinika LF MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Vorlíček, CSc.
6 Oddělení klinické hematologie II. interní kliniky LF UK a FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.
7 Dětská klinika UP a FN Olomouc, přednosta prof. MUDr. Vladimír Mihál, CSc.
8 Hemato-onkologická Lékařské fakulty UP a FN Olomouc, přednosta prof. MUDr. Karel Indrák, DrSc.
9 Hematoloogicko-onkologické oddělení FN Plzeň, přednosta prim. MUDr. Vladimír Koza
10 Oddělení klinické hematologie FN Královské Vinohrady Praha, přednosta doc. MUDr. Tomáš Kozák, Ph.D.
11 Oddělení klinické hematologie FN Motol, Praha, přednostka prim. MUDr. Ivana Hochová
12 Krevní centrum FNsP Ostrava, přednostka prim. MUDr. Zuzana Čermáková
13 Krevní centrum s.r.o., Frýdek-Místek, přednosta prim. MUDr. Boris Bubeník
14 Oddělení klinické hematologie Městské nemocnice Ostrava-Fifejdy, přednostka prim. MUDr. Milena Vránová

Since 2005, registers of patients treated with Thromboreductin® (anagrelid) kept by some centres in the Czech Republic have been supplied with data concerning patients whose treatment with this preparation started in 2004. The purpose of the register is to record responses to therapy by Thromboreductin® and adverse events in patients with essential thrombocytemia and other myeloproliferations, and to subsequently analyse the data. Another objective is to detect predisposition to clinical symptomatology and disease complications. Apart from thrombocyte count, additional risk factors are monitored. The database currently contains data for 336 patients. Initial analyses of data from the register point to the fact that anagrelid is a highly effective thromboreductive agent the administration of which is associated with relatively low incidence of adverse events (11.8 %) of mild and usually transitory nature. The therapeutic objective is attained at a relatively slow rate (according to overall stratification under 400 or under 600 × 109/l thrombocytes), which is probably due to insufficient dose adjustment.

Keywords: anagrelid; essential thrombocytemia; myeloproliferation; register of patients; Thromboreductin®

Received: May 22, 2007; Published: June 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Penka M, Schwarz J, Pavlík T, Pytlík R, Doubek M, Dulíček P, et al.. Essential thrombocytemia and other myeloproliferations with thrombocytemia in the data of the register of patients treated with Thromboreductin® till the end of 2006. Vnitr Lek. 2007;53(6):653-661.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abe Andes W, Noveck RJ, Fleming JS. Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. Thromb Haemost 1984; 52: 325. Go to original source... Go to PubMed...
    2. Barbui T, Barosi G, Grossi A et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica 2004; 89: 215-232. Go to PubMed...
    3. Brière JB. Essential thrombocythaemia. Orphanet J Rare Dis 2007; 2-3: 1-17. Go to original source... Go to PubMed...
    4. Cortelazzo S, Finazzi G, Ruggeri M et al. Hydoxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332: 113. Go to original source... Go to PubMed...
    5. Doubek M, Brychtová Y, Doubek R et al. Anagrelide in pregnancy: report of a case of essential thrombocythaemia. Ann Oncol 2004; 83: 726-727. Go to original source... Go to PubMed...
    6. Elliott MA, Tefferi A. Interferon-α therapy in Polycythemia Vera and essential Thrombocythemia. Semin Thromb Hemost 1997; 23: 463. Go to original source... Go to PubMed...
    7. Green A, Campbell P, Buck G et al. The Medical Research Council PT1 trial in essential thrombocythaemia. Blood 2004; 104: 5a-6a (Abstr. 6). Go to original source...
    8. Harrison CN, Gale RE, Machin SK et al. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999; 93: 417-424. Go to original source...
    9. Jaffe ES, Harris NL, Stein H et al (eds). World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press 2001: 352.
    10. Kralovics R, Teo SS, Li S et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006; 108: 1377-1380. Go to original source... Go to PubMed...
    11. Landolfi R, Rocca B, Patrono C. Bleeding and thrombosis in myeloproliferative disorders: mechanism and treatment. Crit Rev Oncol Hematol 1995; 20: 203-222. Go to original source... Go to PubMed...
    12. Messa RA, Tefferi A, Jacobsen SJ et al. Population-based incidence and survival figures in Essential Thrombocythemia and agnogenic myeloid meta-plasia: an Olmsted County study. Am J Hematol 1999; 61: 10-15. Go to original source... Go to PubMed...
    13. Michiels JJ, Kutti J, Stark P et al. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. Netherlands J Med 1999; 54: 46-62. Go to original source... Go to PubMed...
    14. Michiels JJ, De Raeve H, Hebeda K et al. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders. Leuk Res 2007; In press. Go to original source... Go to PubMed...
    15. Michiels JJ, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 2002; 76: 133-145. Go to original source... Go to PubMed...
    16. Murphy S, Peterson P, Iland H et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29-39.
    17. Penka M, Schwarz J, Pytlík R et al. Doporučený postup diagnostiky a terapie esenciální trombocytemie a trombocytemie provázející myeloproliferativní onemocnění. Vnitř Lék 2005; 51: 741-751.
    18. Penka M, Doubek M, Schwarz J et al. Anagrelid v léčbě esenciální trombocytemie a dalších myeloproliferací s trombocytemií sledovaných v registru pacientů ČR. Vnitř Lék 2006; 52: 498-503. Go to PubMed...
    19. Petrides PE Anagrelid: decade of clinical experiences with its use for the treatment of primary thrombocythaemia. Expert Opin Pharmacother 2004; 5: 1781-1798. Go to original source... Go to PubMed...
    20. Petrides PE, Beykirch MK, Trapp OM. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experiences in 48 patients in Germany. Eur J Haematol 1998; 61: 71. Go to original source... Go to PubMed...
    21. Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 1997; 34: 51.
    22. Pytlík R, Cmunt E, Kleibl Z et al. Úloha anagrelidu v léčbě esenciální trombocytemie. Transfuz Hematol Dnes 2004; 10: 154-160.
    23. Schwarz J, Pytlík R, Doubek M et al. Analysis of risk factors: the rationale of the guidelines for diagnosis and treatment of Ph-negative myeloproliferative disorders with thrombocythemia of the Czech Hematological Society. Sem Thromb Haemost 2006; 32: 231-245. Go to original source... Go to PubMed...
    24. Schwarz J, Markova J, Volkova Z et al. The majority of patients with Ph-negative MPD with thrombocythemia and major thrombosis have either inherited thrombophila or JAK2 V617F gene mutation. Abstr. Second ESH Euroconference on Myeloproliferative Disorders: Molecular Pathogenesis and Therapy, Madeira, poster 23, 2006.
    25. Silverstein MN, Tefferi A. Treatment of essential thrombocythemia with anagrelide. Semin Hematol 1999; 36: 23-25.
    26. Solberg LA jr, Oles KJ, Tarach J et al. The effects of anagrelid on human megakaryocytopoiesis. Blood 1989; 6274 (Suppl 1): 20a.
    27. Steurer M, Gastl G, Jedrzejczak W et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 2004; 101: 2239-2246. Go to original source... Go to PubMed...
    28. Storen EC, Tefferi A Long-term use of anagrelid in young patients with essential thrombocythemia. Blood 2001; 97: 836-866. Go to original source... Go to PubMed...
    29. Thiele J, Kvasnicka HM, Graeff AS et al. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): A retrospective clinicopathological study of 120 patients. Am J Hematol 2002; 70: 283-291. Go to original source... Go to PubMed...
    30. Thiele J, Kvasnicka HM, Zankovich R et al. Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis. Ann Hematol 2001; 80: 160-165. Go to original source... Go to PubMed...
    31. Tsimberidou MA, Colburn DE, Welch MA et al. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol 2003; 52: 229-234. Go to original source... Go to PubMed...
    32. Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol 2001; 66: 152. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.